Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
ConclusionsThe discovery of disproportionality signals could potentially prompt improved awareness of toxicities for abemaciclib, and the results of time to onset, serious and non-serious reports, and clinical priority analyses provided some supporting evidence for clinicians to manage adverse events.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Hormones | Interstitial Lung Disease | Study | Thrombosis | Toxicology | Women